oAlert.pl

Recalled Medicines & supplements – Current GIS Alerts 2026

Found 685 recalled products in the Medicines & supplements category. Check batch numbers, shops, and hazard information.

Common hazards in this category

All recalled products

Egoropal – recalled product

Egoropal

CRITICAL 08.05.2024

The medicinal product does not meet quality requirements due to a negative test result for the particle size analysis parameter in the prolonged-release suspension for injection. Potential effects: abnormal dose release, reduced efficacy or increased risk of adverse reactions.

Zodgane – recalled product

Zodgane

MEDIUM 08.05.2024

Test result out of specification for particle size distribution D(0.9) (batch 1254), indicating suspected failure to meet quality requirements. Potential effects: possible reduced efficacy of the medicine.

Ibuprofen Dr. Max – recalled product

Ibuprofen Dr. Max

MEDIUM 22.04.2024

The product does not meet quality requirements due to a negative result for the loss on drying parameter; only a medicine compliant with the specification can be considered effective and safe. Potential effects: possibly reduced analgesic effect and uncertain treatment safety.

Qutiro – recalled product

Qutiro

CRITICAL 29.03.2024

Suspected microbiological contamination of the infusion solution, linked with detection of Klebsiella pneumoniae ESBL in patients’ blood cultures and serious unexpected adverse reactions (chills, chest pain, convulsions). Potential effects: sepsis, severe systemic reactions, life-threatening conditions.

Qutiro – recalled product

Qutiro

CRITICAL 29.03.2024

After Qutiro infusion, patients developed chills, chest pain and seizures; blood cultures grew Klebsiella pneumoniae ESBL, indicating infection and a real threat to health or life. Potential effects: sepsis, septic shock, severe complications, death.

Qutiro – recalled product

Qutiro

CRITICAL 28.03.2024

In several patients after Qutiro infusion, chills, chest pain and convulsions occurred; blood cultures grew Klebsiella pneumoniae ESBL. A microbiological contamination of the sterile infusion product is suspected, posing a real threat to patients’ health or life. Potential effects: severe bloodstream infection, septic shock, life‑threatening complications.

Omegaflex special – recalled product

Omegaflex special

CRITICAL 27.03.2024

An improperly made seal of the outer bag allowed air and oxygen to enter, which could change the properties of the lipid emulsion and poses a real risk to patients’ health and life. Potential effects: complications during infusion, lack of treatment efficacy, adverse reactions.

Omegaflex special – recalled product

Omegaflex special

CRITICAL 27.03.2024

An improperly made package seal allowed air and oxygen to enter the bag, which could change the medicine’s properties and lead to adverse health effects and a real risk to patients’ health and potentially also life. Potential effects: complications, lack of efficacy, possible severe reactions.

ACC classic – recalled product

ACC classic

CRITICAL 22.03.2024

The presence of solid particles from the sealing insert in the medicinal product in the form of an oral solution creates a high probability of swallowing them, which, depending on the size and shape of the particles, may lead to unpredictable, direct, negative health effects, potentially life‑threatening. Potential effects: irritation of the gastrointestinal tract, mechanical injuries, complications endangering health or life.

ACC classic – recalled product

ACC classic

CRITICAL 22.03.2024

The presence of solid particles originating from the closure’s sealing insert has been detected in the oral solution. Swallowing them, depending on their size and shape, may lead to unpredictable adverse health effects. Potential effects: gastrointestinal irritation, mechanical complications, life-threatening conditions in extreme cases.

Auroverin MR – recalled product

Auroverin MR

MEDIUM 20.03.2024

It was found that the batch does not meet quality requirements due to a negative test result for the mebeverine hydrochloride release parameter, which may lead to improper release and reduced therapeutic efficacy. Potential effects: lack of efficacy, worsening of disease symptoms.

Auroverin MR – recalled product

Auroverin MR

MEDIUM 20.03.2024

This batch does not meet the specified quality requirements due to a negative test result for the mebeverine hydrochloride release parameter. Potential effects: reduced effectiveness in treating intestinal disorders, possible worsening of disease symptoms.

Paracetamol Aflofarm – recalled product

Paracetamol Aflofarm

HIGH 06.03.2024

It was found that a homogeneous suspension could not be obtained and sediment remained at the bottom of the bottle, which may lead to incorrect dosing of the medicine, including in children from three months of age. Potential effects: lack of efficacy or overdose, possible adverse reactions and complications.

Levosimendan Kabi – recalled product

Levosimendan Kabi

CRITICAL 04.03.2024

The product was found to be contaminated with particles visible to the naked eye in 9 of 20 tested vials of the 2.5 mg/ml concentrate for solution for infusion, which means it does not meet quality specification requirements. Potential effects: complications after intravenous administration, emboli, local reactions, lack of therapy safety.

Levosimendan Kabi – recalled product

Levosimendan Kabi

CRITICAL 04.03.2024

Testing by NIL showed that the product does not meet quality specification requirements regarding contamination with particles visible to the naked eye; in 9 of 20 tested vials such particles were found. Potential effects: complications after intravenous infusion, embolism, inflammation, local or systemic reactions.

Misintu – recalled product

Misintu

CRITICAL 12.02.2024

In the prepared solution for injection, visible insoluble particles of unknown nature and origin were detected, which may enter the patient’s bloodstream and cause unpredictable negative health effects. Potential effects: embolic complications, vascular damage, severe systemic reactions, life-threatening conditions.

Misintu – recalled product

Misintu

CRITICAL 12.02.2024

Visible to the naked eye, insoluble particles of unknown nature and origin were found in prepared solutions of the medicinal product in the form of an injection solution, which may create a real danger of these particles entering the patient's bloodstream. Potential effects: embolic complications, vascular damage, unpredictable systemic reactions.

Vblaast 10 – recalled product

Vblaast 10

CRITICAL 09.02.2024

Visible, unidentified crystals were found in the medicinal product in the form of an injection solution, creating a real danger of crystals entering the patient’s bloodstream and causing serious, unpredictable health consequences. Potential effects: thrombotic complications, vascular damage, embolism, severe systemic complications.

Reparil Gel N – recalled product

Reparil Gel N

CRITICAL 09.02.2024

Test results showed a value above the limit for aescinol content – a degradation product of the active substance – which constitutes a real and direct risk to patients’ health or life until the cause of the deviation is clarified. Potential effects: possible toxicological effects, lack of treatment safety, complications.

Vblaast 10 – recalled product

Vblaast 10

CRITICAL 09.02.2024

Visible to the naked eye crystals of unidentified origin were found in the medicinal product in the form of a solution for injection; their entry into the patient’s bloodstream may lead to unpredictable adverse health effects. Potential effects: vascular complications, organ damage, severe systemic complications.

What to do if you bought a recalled product?

If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.